PURPOSE: This study evaluated the efficacy and adverse effects of Imatinib therapy to advanced Dermatofibrosarcoma protuberan (DFSP) and Sunitinib therapy to advanced Dermatofibrosarcoma protuberan (DFSP) after Imatinib resistance. METHODS: We analyzed the efficacy, adverse effects and survival of 95 patients with locally advanced or metastatic DFSP treated by Imatinib between January 2003 and December 2009, and also analyzed the efficacy and adverse effects of 30 patients after Imatinib failure between January 2008 and December 2011. RESULTS: In all 95 patients treated by Imatinib, 16 had complete response (CR, 16.8%), 44 had partial response (PR, 46.3%), 23 had stable disease (SD, 24.2%) and 12 had progressive disease (PD, 12.6%). The DCR (CR+PR+SD) was 87.4%. The median PFS was 23 months and the OS was 40 months. For 30 patients had Sunitinib treatment after Imatinib failure, 2 had CR (6.7%), 10 had PR (33.3%), 12 had SD (40%) and 6 had PD (20%). The disease control rate (DCR=CR+PR+SD) was 73.3%. The progression free survival (PFS) of CR and PR patients were 22 months and 20 months respectively. The PFS of 12 SD was 18 months, and overall survival (OS) was 28 months. And the median PFS and OS of all 30 patients were 19 and 27 months respectively after Sunitinib treatment. Most of the Imatinib-induced adverse effects are of grade 1-2, including nausea, water retention/edema, fatigue, etc. CONCLUSION: Imatinib has been proven to be effective and well-tolerated in the treatment of locally advanced or inoperable patients with DFSP. After Imatinib failure, Sunitinib therapy showed good clinical efficacy and tolerated adverse effects as a new treatment option for such patients.
PURPOSE: This study evaluated the efficacy and adverse effects of Imatinib therapy to advanced Dermatofibrosarcoma protuberan (DFSP) and Sunitinib therapy to advanced Dermatofibrosarcoma protuberan (DFSP) after Imatinib resistance. METHODS: We analyzed the efficacy, adverse effects and survival of 95 patients with locally advanced or metastatic DFSP treated by Imatinib between January 2003 and December 2009, and also analyzed the efficacy and adverse effects of 30 patients after Imatinib failure between January 2008 and December 2011. RESULTS: In all 95 patients treated by Imatinib, 16 had complete response (CR, 16.8%), 44 had partial response (PR, 46.3%), 23 had stable disease (SD, 24.2%) and 12 had progressive disease (PD, 12.6%). The DCR (CR+PR+SD) was 87.4%. The median PFS was 23 months and the OS was 40 months. For 30 patients had Sunitinib treatment after Imatinib failure, 2 had CR (6.7%), 10 had PR (33.3%), 12 had SD (40%) and 6 had PD (20%). The disease control rate (DCR=CR+PR+SD) was 73.3%. The progression free survival (PFS) of CR and PR patients were 22 months and 20 months respectively. The PFS of 12 SD was 18 months, and overall survival (OS) was 28 months. And the median PFS and OS of all 30 patients were 19 and 27 months respectively after Sunitinib treatment. Most of the Imatinib-induced adverse effects are of grade 1-2, including nausea, water retention/edema, fatigue, etc. CONCLUSION:Imatinib has been proven to be effective and well-tolerated in the treatment of locally advanced or inoperable patients with DFSP. After Imatinib failure, Sunitinib therapy showed good clinical efficacy and tolerated adverse effects as a new treatment option for such patients.
Authors: W B Bowne; C R Antonescu; D H Leung; S C Katz; W G Hawkins; J M Woodruff; M F Brennan; J J Lewis Journal: Cancer Date: 2000-06-15 Impact factor: 6.860
Authors: Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245
Authors: J Nishio; H Iwasaki; M Ishiguro; Y Ohjimi; S Yo; T Isayama; M Naito; M Kikuchi Journal: Genes Chromosomes Cancer Date: 2001-03 Impact factor: 5.006
Authors: Ellen Weisberg; Paul W Manley; Sandra W Cowan-Jacob; Andreas Hochhaus; James D Griffin Journal: Nat Rev Cancer Date: 2007-05 Impact factor: 60.716
Authors: Suzanne George; Priscilla Merriam; Robert G Maki; Annick D Van den Abbeele; Jeffrey T Yap; Timothy Akhurst; David C Harmon; Gauri Bhuchar; Margaret M O'Mara; David R D'Adamo; Jeffrey Morgan; Gary K Schwartz; Andrew J Wagner; James E Butrynski; George D Demetri; Mary L Keohan Journal: J Clin Oncol Date: 2009-05-18 Impact factor: 44.544
Authors: Lesley J Murray; Tinya J Abrams; Kelly R Long; Theresa J Ngai; Lisa M Olson; Weiru Hong; Paul K Keast; Jacqueline A Brassard; Anne Marie O'Farrell; Julie M Cherrington; Nancy K Pryer Journal: Clin Exp Metastasis Date: 2003 Impact factor: 5.150
Authors: Kirill I Kirsanov; Ekaterina A Lesovaya; Timur I Fetisov; Beniamin Yu Bokhyan; Gennady A Belitsky; Marianna G Yakubovskaya Journal: Sarcoma Date: 2020-03-31